Əsas səhifə

Çap

Əks əlaqə

İnfo
Glycaemic control for slowing the progression of microvascular complications in diabetes mellitus

Mündəricat

Glycaemic control for slowing the progression of microvascular complications in diabetes mellitus

Sübutlu məlumatların xülasələri
10.08.2017 • Sonuncu dəyişiklik 10.08.2017
Editors

Intensive glycaemic control is effective in reducing the risk of microvascular complications in people with type 1 diabetes.

A Cochrane review included 12 studies with a total of 2 230 adults and children. Under intensive glucose control, the risk of developing microvascular complications was reduced compared to conventional treatment for retinopathy, nephropathy, and neuropathy . Regarding the progression of these complications after manifestation, the effect was weaker (retinopathy) or possibly not existent (nephropathy) . Major macrovascular outcomes (stroke and myocardial infarction) occurred very rarely. intensive glucose control increased the risk for severe hypoglycaemia, however the results were heterogeneous and only the 'Diabetes Complications Clinical Trial' (DCCT) showed a clear increase in severe hypoglycaemic episodes under intensive treatment. A subgroup analysis according to the baseline haemoglobin A1c (HbA1c) of participants in the trials (low quality evidence) suggests that the risk of hypoglycaemia is possibly only increased for patients who started with relatively low HbA1c values (< 9.0%). Several of the included studies also showed a greater weight gain under intensive glucose control, and the risk of ketoacidosis was only increased in studies using insulin pumps in the intensive treatment group (very low quality evidence).

Intensive glucose control versus conventional glucose control for microvascular complications type 1 diabetes
OutcomesRelative effect (95% CI) Assumed risk - Control Corresponding risk - Intensive treatment (95% CI) No of participants (studies) Quality of evidence
Manifestation of retinopathy Follow-up: 5 - 6.5 years RR 0.27 (0.18 to 0.42)232 per 1000 63 per 1000 (42 to 97) 768 (2) High
Manifestation of nephropathy Follow-up: 3.5 - 6.5 years RR 0.56 (0.46 to 0.68) 284 per 1000 159 per 1000 (131 to 193)1475 (3) Moderate
Manifestation of neuropathy Follow-up: 5 - 6.5 yearsRR 0.35 (0.23 to 0.53) 139 per 1000 49 per 1000 (32 to 74) 1203 (3) High
Progression of retinopathy Follow-up: 5 - 6.5 years RR 0.61 (0.49 to 0.76) 387 per 1000 236 per 1000 (190 to 294)764 (2) Moderate
Progression of nephropathy Follow-up: 5 - 6.5 years RR 0.79 (0.37 t0 1.70) 14 per 1000 11 per 1000 (5 to 24) 179 (3) Very low

A topic in Clinical Evidence summarizes the results of one systematic review including 16 RCTs. Compared to conventional control, intensive glycaemic control reduced progression of nephropathy in people with type 1 diabetes and either normal albumin excretion of microalbuminuria (7 RCTs, 266 people, OR 0.34, 95% CI 0.20 to 0.58). Severe hypoglycaemia increased by 9.1 episodes/100 person years, 95% CI -1.4 to 19.6.

Ədəbiyyat

  1. Shlipak M. What are the effects of treatments in people with type 1 diabetes and early nephropathy. Clinical Evidence 2004;12:821-823.
  2. Fullerton B, Jeitler K, Seitz M et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014;(2):CD009122.